Cargando…
A Comparative Study of Immunogenicity, Antibody Persistence, and Safety of Three Different COVID-19 Boosters between Individuals with Comorbidities and the Normal Population
Data on immunogenicity, immune response persistency, and safety of COVID-19 boosters in patients with comorbidities are limited. Therefore, we aimed to evaluate three different boosters’ immunogenicity and safety in individuals with at least one underlying disease (UD) (obesity, hypertension, and di...
Autores principales: | Ashrafian, Fatemeh, Bagheri Amiri, Fahimeh, Bavand, Anahita, Zali, Mahsan, Sadat Larijani, Mona, Ramezani, Amitis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459403/ https://www.ncbi.nlm.nih.gov/pubmed/37631944 http://dx.doi.org/10.3390/vaccines11081376 |
Ejemplares similares
-
Characterization of long COVID-19 manifestations and its associated factors: A prospective cohort study from Iran
por: Sadat Larijani, Mona, et al.
Publicado: (2022) -
A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports
por: Sadat Larijani, Mona, et al.
Publicado: (2023) -
Evaluation of PastoCovac plus vaccine as a booster dose on vaccinated individuals with inactivated COVID-19 vaccine
por: Farahmand, Behrokh, et al.
Publicado: (2023) -
PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals
por: Ramezani, Amitis, et al.
Publicado: (2023) -
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals
por: Eybpoosh, Sana, et al.
Publicado: (2023)